节点文献

家庭双水平气道正压通气治疗重叠综合征的疗效观察

Clinical effect observation of double-level positive airway pressure ventilation in the treatment of patients with overlapping syndrome

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 郭伟洪袁小玲夏秀琼黄锡坤缪卓峰

【Author】 GUO Weihong;YUAN Xiaoling;XIA Xiuqiong;HUANG Xikun;MIAO Zhuofeng;Respiratory Department,the People’s Hospital of Zhongshan City;

【机构】 广东省中山市人民医院呼吸内科

【摘要】 目的探讨家庭双水平气道正压通气(BiPAP)治疗重叠综合征(OS,慢性阻塞性肺疾病-睡眠呼吸暂停低通气综合征)3个月的疗效。方法随机入选2014年7月2016年9月本院门诊就诊的符合入选标准的OS患者44例,随机分为两组:对照组22例和试验组22例,对照组给予常规治疗,包括行为干预治疗及常规药物治疗,试验组在常规治疗基础上加用每天夜间8h的BiPAP治疗。对两组患者治疗1、3个月后进行门诊随访,比较两组患者治疗1、3个月后疗效指标:呼吸困难评分(mMRC)、嗜睡评分量表(ESS)、多导睡眠监测指标(睡眠紊乱指数AHI、夜间最低氧饱和度minSPO2)、晨起血气分析指标(PO2、PCO2)及3个月内慢性阻塞性肺疾病(COPD)急性加重次数的差异。结果两组患者均能耐受相关治疗,无一例脱失;常规治疗及BiPAP治疗均能改善患者1、3个月mMRC评分、ESS评分、AHI、minSPO2、晨起PO2和PCO2指标(P<0.05)。与常规治疗组相比,随着治疗时间延长,BiPAP治疗更能改善mMRC评分、ESS评分、AHI、minSPO2、晨起PCO2指标。两组患者3个月内COPD急性加重的次数差异无统计学意义(P>0.05)。结论家庭BiPAP治疗可行性良好,可显著逐渐改善患者3个月的预后,值得在OS患者中推广应用。

【Abstract】 Objective To investigate the clinical effect of 3 months of family BiPAP therapy on COPD-OSAHS Overlapsyndrome(OS) patients. Methods Forty four OS outpatients of our hospital from Jul 2014 to Sep 2016 were recruited and randomly divided into 2 groups:control group(n=22) and trial group(n=22).Patients in the control group was given general therapy,included behavior intervention and regular medication therapy.Patients in the trial group was given BiPAP treatment of 8 h at nigh on the basis of routine treatment. The patients were asked to attend the outpatient clinic after 1 month and 3 months.and complete the associated tests. efficacy indexes [dyspnea symptom score(mMRC),Epworth sleepiness scale(ESS),the apnoea hyponea index(AHI),the lowest sleep SpO2(minSPO2),blood gas analysis in the morning(PO2,PCO2) and the times of acute exacerbation of COPD] between two groups after 1 month and 3 months were compared. Results All the patients were completed the 3 months follow-up and compliance with the treatment.mMRC score,ESS score,AHI、minSPO2、PO2 and PCO2 were all improved in both groups after treatment(P < 0.05).mMRC score,ESS score,AHI、minSPO2 and PCO2 were significant improved in trail group than control group.There was no significant difference in number of acute attack of COPD between the two groups(P > 0.05).Conclusion Family BiPAP therapy has good feasibility,and can improve the outcomes of OS patients.It is worth using widely in patients with OS.

【基金】 广东省中山市科技计划项目(2014A1FC090)
  • 【文献出处】 中国医药科学 ,China Medicine and Pharmacy , 编辑部邮箱 ,2018年01期
  • 【分类号】R563.9;R766
  • 【被引频次】2
  • 【下载频次】37
节点文献中: 

本文链接的文献网络图示:

本文的引文网络